Is there any Indian generic version of Midostaurin?
Midostaurin (Midostaurin) is a multi-target tyrosine kinase inhibitor that is clinically used to treat some specific types of hematological tumors, especially acute myeloid leukemia (AML) and kinase-positive systemic mastocytosis (SM-AHN).
There are generic versions of Midostaurin available in India. Currently Midostaurin is not available in China, so patients cannot purchase it domestically. Midostaurin abroad is divided into original drugs and generic drugs. The cheaper original version is the Indian version, which costs more than 10,000 yuan. Others include Turkish and European original drugs, which cost tens of thousands to hundreds of thousands, which are relatively expensive. Generic drugs are mainly Indian generic drugs, which cost about several thousand yuan per box. They are much cheaper than the original drug, and the drug ingredients are basically the same as the original drug.

Midostaurin's primary mechanism of action involves inhibition of multiple tyrosine kinase targets. It is an inhibitor of FLT3 (Fms-like tyrosine kinase3), a cell surface receptor tyrosine kinase with aberrant activity often seen in AML patients. In addition, midostaurin also inhibits KIT, PDGFRα, PDGFRβ, VEGFR and other kinases. These effects help control the proliferation of malignant tumor cells and promote them to undergo apoptosis, thereby achieving therapeutic effects.
The use of midostaurin may be associated with a range of side effects, including but not limited to nausea, vomiting, diarrhea, itchy skin, headache, fatigue, low platelet count, low white blood cell count, abnormal liver function, cardiac arrhythmia, and bleeding. Patients need to be monitored regularly during use to ensure safety and to promptly address possible side effects.
Patients need to be closely monitored for side effects and safety while taking midostaurin. This includes regular blood tests, electrocardiogram monitoring, and liver function monitoring. During treatment, doctors will pay close attention to the patient's symptoms and reactions and make adjustments as needed.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)